Molbio Diagnostics IPO Opens: GMP at 16% Premium

Molbio Diagnostics’ initial public offering (IPO) opened for bidding on August 10, 2026. The offer, valued at approximately ₹940 crore, suggests a 16 percent premium over its upper price band. It closes on August 12.

IPO at a Glance

• Total IPO Value: approximately ₹940 crore
• Fresh Issue: ₹200 crore
• Offer for Sale (OFS): ₹739.70 crore
• Price Band: ₹768 to ₹807 per share
• Grey Market Premium (GMP): ₹132
• Estimated Listing Price: ₹939
• Premium over upper price band: 16 percent

Molbio Diagnostics specializes in point-of-care molecular diagnostic platforms. They focus on rapid and cost-effective solutions for various diseases.

Proceeds from the fresh issue will fund capital expenditure for R&D facilities, a Centre of Excellence, and plant and machinery in Goa and Visakhapatnam. General corporate purposes are also included.

Brokerages Weigh In

Brokerages have largely recommended subscribing to the IPO for long-term investment. They cite the company’s strong market position and financial health.

• Swastika noted a favorable long-term outlook, healthy return ratios, and margin expansion. Valuations align with industry averages.
• SBI Securities highlighted robust financial performance from FY24-26, with significant growth in revenue, EBITDA, and adjusted PAT. They consider the issue reasonably valued.
• Master Capital identified Molbio Diagnostics as a strong long-term opportunity. They pointed to its proprietary Truenat platform, competitive position, and global patent portfolio.

Molbio Diagnostics shares are slated for listing on both the BSE and NSE. This is expected on August 17.